United Therapeutics Corp. (UTHR) Tops Q1 EPS Views
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $517.71 -1.54%
Revenue Growth %: +1.1%
Financial Fact:
Net income per diluted common share (in dollars per share): 3.5
Today's EPS Names:
HFBL, PBHC, PBNK, More
Revenue Growth %: +1.1%
Financial Fact:
Net income per diluted common share (in dollars per share): 3.5
Today's EPS Names:
HFBL, PBHC, PBNK, More
Join SI Premium – FREE
United Therapeutics Corp. (Nasdaq: UTHR) reported Q1 non-GAAP EPS of $1.29, $0.65 better than the analyst estimate of $0.64. Revenue for the quarter came in at $165.6 million versus the consensus estimate of $178.02 million.
United Therapeutics reported non-GAAP EPS of $1.13 in Q210.
United Therapeutics reported non-GAAP EPS of $1.13 in Q210.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- United Therapeutics ralinepag PAH study published in The Lancet
- Bogota Financial Corp. (BSBK) Reports Q2 EPS of $0.06
- Pinnacle Bank (PBNK) Tops Q2 EPS by 25c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
